These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9696954)

  • 1. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients.
    Contin M; Riva R; Martinelli P; Albani F; Baruzzi A
    Eur J Clin Pharmacol; 1998 Jun; 54(4):303-8. PubMed ID: 9696954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease.
    Roos RA; Tijssen MA; van der Velde EA; Breimer DD
    Clin Neurol Neurosurg; 1993 Sep; 95(3):215-9. PubMed ID: 8242964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    Clin Neuropharmacol; 2012; 35(2):67-72. PubMed ID: 22377973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.
    Modi NB; Mittur A; Rubens R; Khanna S; Gupta S
    Clin Neuropharmacol; 2019; 42(1):4-8. PubMed ID: 30520758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.
    Pahwa R; Lyons K; McGuire D; Dubinsky R; Hubble JP; Koller WC
    Neurology; 1996 Apr; 46(4):1059-62. PubMed ID: 8780091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
    Hammerstad JP; Woodward WR; Nutt JG; Gancher ST; Block GA; Cyhan G
    Clin Neuropharmacol; 1994 Oct; 17(5):429-34. PubMed ID: 9316692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Clin Neurol Neurosurg; 1989; 91(4):303-9. PubMed ID: 2555090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability.
    Contin M; Riva R; Martinelli P; Procaccianti G; Baruzzi A
    Clin Neuropharmacol; 1989 Feb; 12(1):75-81. PubMed ID: 2713868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease.
    Hutton JT; Albrecht JW; Román GC; Kopetzky MT
    Arch Neurol; 1988 Jan; 45(1):55-7. PubMed ID: 3276299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
    Benetello P; Furlanut M; Zara G; Baraldo M; Hassan E
    Eur Neurol; 1993; 33(1):69-73. PubMed ID: 8440292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease.
    Nelson MV; Berchou RC; LeWitt PA; Kareti D; Galloway MP
    Neurology; 1990 Jan; 40(1):70-4. PubMed ID: 2296385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
    J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients.
    Baruzzi A; Contin M; Riva R; Procaccianti G; Albani F; Tonello C; Zoni E; Martinelli P
    Clin Neuropharmacol; 1987 Dec; 10(6):527-37. PubMed ID: 3427559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Rytary
    Mittur A; Gupta S; Modi NB
    Clin Pharmacokinet; 2017 Sep; 56(9):999-1014. PubMed ID: 28236251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations.
    Modi NB; Mittur A; Dinh P; Rubens R; Gupta S
    Clin Neuropharmacol; 2019; 42(5):149-156. PubMed ID: 31306216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.